ESMO

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer

October 19th 2025, 8:44pm

Article

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Tiragolumab Treatment Combo Misses Mark in Advanced Liver Cancer

October 19th 2025, 8:13pm

Article

Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.

Imfinzi Combo Improves Progression Free Survival in Ovarian Cancer

October 19th 2025, 7:50pm

Article

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Loqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer

October 19th 2025, 7:26pm

Article

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Supplemental Xtandi Does Not Improve Metastasis-Free Survival in High-Risk Prostate Cancer

October 19th 2025, 6:57pm

Article

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study

October 19th 2025, 6:37pm

Article

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer

October 19th 2025, 6:18pm

Article

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.

Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial

October 19th 2025, 5:49pm

Article

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer.

Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer

October 19th 2025, 5:09pm

Article

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

Tiragolumab Plus Tecentriq Doesn’t Improve NSCLC Outcomes

October 19th 2025, 1:55am

Article

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.